Lyrica (pregabalin)
Step Therapy
(Draft)

Lyrica will be approved for:

1. Diagnosis of seizure disorders or neuropathic pain associated with a spinal cord injury OR
2. Diagnosis of fibromyalgia, postherpetic neuralgia, or diabetic neuropathy AND
3. A history of therapeutic failure of gabapentin at the maximum tolerable dose (1800 mg/day) for thirty (30) days unless one there the potential for an adverse drug-drug interaction, an adverse drug-disease interaction, intolerable side effects or an allergy to gabapentin exists. (In cases of renal impairment, doses may be adjusted based on the degree of impairment.)

(This criteria will be implemented with the new Preferred Drug List on January 1, 2013.)

Utilization June 1, 2011 - June 30, 2012

<table>
<thead>
<tr>
<th>Drug</th>
<th>No of Prescriptions</th>
<th>Average Units/Rx</th>
<th>Total Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lyrica</td>
<td>39,372</td>
<td>68.51</td>
<td>$7,458,685.55</td>
</tr>
<tr>
<td>Gabapentin</td>
<td>105,663</td>
<td>180.05</td>
<td>$3,260,577.27</td>
</tr>
</tbody>
</table>


5,665 members with prescriptions for Lyrica
4,490 of these members also had concurrent prescriptions for opioids